William Gill
Medical · Wauchula, FLNPI 1427164334
Payments from drug & device makers
Across 126 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$525
- Merck$306
- Boehringer Ingelheim$269
- GSK$240
- Lilly USA, LLC$204
- Bayer$103
- plus $597 from 13 others
What the payments were for
- Food & beverage$2,244100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $525 |
| Merck | 20 | $306 |
| Boehringer Ingelheim | 13 | $269 |
| GSK | 15 | $240 |
| Lilly USA, LLC | 13 | $204 |
| Bayer | 4 | $103 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| Abbott | 4 | $91 |
| Exact Sciences | 4 | $86 |
| AbbVie | 4 | $81 |
| Novo Nordisk | 4 | $63 |
| Pfizer | 2 | $43 |
| Dexcom, Inc. | 2 | $38 |
| Amgen | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$2,244 in reported general payments places this provider in the 70th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 95 | $95,537 |
| OzempicSemaglutide | 97 | $88,021 |
| EliquisApixaban | 95 | $66,854 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $55,126 |
| FarxigaDapagliflozin Propanediol | 66 | $53,316 |
| MounjaroTirzepatide | 32 | $42,340 |
| TrulicityDulaglutide | 17 | $26,703 |
| RybelsusSemaglutide | 27 | $26,374 |
| XareltoRivaroxaban | 17 | $24,966 |
| JanuviaSitagliptin Phosphate | 22 | $19,753 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $19,206 |
| EntrestoSacubitril/Valsartan | 13 | $19,106 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $13,652 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $11,422 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $9,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $63 | $114,395124 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $525 | $108,441134 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $269 | $104,895114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $204 | $69,04349 claims |
| PfizerEliquis | $43 | $66,85495 claims |
| MerckJanuvia | $306 | $19,75322 claims |
| NovartisEntresto | $14 | $19,10613 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $96 | $11,42213 claims |
| AbbVieCreon | $81 | $8,95611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,031 medical providers in Florida.
Other medical in Wauchula
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.